Distiloti has made its first sale of several surgical robots in the US Adventhlth, which operates 50 hospitals in nine states, selecting the dexator system of the distiloti to support the development of minimum invasive procedures. It has already completed its first matters with the system.
General Surgeon Dr. “We are excited to complete our first cases with dexter as Carlos Ortis-Artiz MD said that we bring robotic surgery to our outpatient department.” “As we expand our abilities, we focus on solutions that align with our goals for flexibility and efficiency.”
Dexter is designed to simplify operations and widen access to robots Surgery Worldwide, according to distilty. Loosene, Switzerland-based Company The outpatient departments of the hospital provide their technology to the surgical centers (ASCs). DistiLotty of American offices in Cleveland stated that Dexter is commercially available in the US and Europe.
Dexter designed for flexibility
Demand for surgical robotics continues to increase, and more high-vantage soft-high procedures-as the inguinal hernia repair and cholecystactomy-out patient settings. In response, Health care Facilities are looking for solutions that match their clinical and operating requirements. However, their focus on efficiency and patient experience makes the existing soft-high robot impractical due to size, operational complexity and costs, the distiloti said.
The company said it could adequately move the dexter between the operating room (ORS) to be mobile and small, settled quickly, and integrated into existing processes. This turnover can reduce the time, maximize throwput, and increase the number of patients that benefit from minimum invasive care, distiloti said.
The company claimed that Dexter is the only System Available in the US and European markets with both a sterile console and a completely open architecture. The sterile console enables surgeons to perform bedside tasks and then immediately returns to operation without a change in sterility or robot redocking.
The console keeps the surgeon closer to the patient, as desired as desired supports infection between laparoscopic and robotic techniques, and or increases communication with teams, the distilty said.
The open architecture of the dexter supports the use of preferred devices and or technologies that are already available in convenience, reducing the need to purchase expensive new techniques. Dexter comes with a suit of a complete collapsed robot devices to enhance dexter mastery and accuracy.
The architecture enables existing and compatibility with future or technologies, including visualization systems and advanced equipment, for cost -effective supply chain operations. Together, these features give surgeons the ability to use workflows that they believe is best for each patient.
Dustaloti CEO Greg Roshe said, “This multi-system cell underlines how the health system is looking for more flexible solutions that bring robotics benefits to ORS on their sites.” “Dexter is designed to meet the realities of outpatient surgery, without compromising the existing practices.”
Distiloti creates speed in American expansion
The dexter robotic surgery system is currently authorized to repair adult hernia and use adult hernia for adults in the US in Europe only only in Europe, the robot aims to assist in accurate control of laparoscopic surgical devices during urinary, general and gynecological processes.
Dexter has been involved in more than 2,000 processes completed globally in general, gynecology and urinary specifics. Distiloti stated that globally focus on making robot surgery more accessible on more of the site of care globally.
In March, the company said it had completed the first American sales and delivery of Dexter to Memorial Harman Health System. The integrated system serves South East Texas and Greater Houston community with more than 270 care distribution sites including 17 hospitals.
After that month, it was announced that the Northtown ASC had chosen Dexter for a robot outpatient. Surgery,
This year, distiloti also completed two studies, Nest Studies (NCT06473688) focused on cholecystomy and hyper study (NCT06473675), which belongs to the historomy. Distiloti has also launched its Sacrocopopexy clinical study, with the first patient nominated in Q1 2025. The company said that these studies will help it better meet the developments of healthcare providers.
editor’s Note: This article is syndicated Robot report Cybuling site Mass,
https://www.youtube.com/watch?v=- x3mxsnnthc
